Cargando…
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
The aim of this study is to elucidate the clinical significance of prostate-specific membrane antigen (PSMA) expression in circulating tumor cells (CTCs) from castration-resistant prostate cancer (CRPC) patients. We analyzed a total of 203 CTC samples from 79 CRPC patients to investigate the proport...
Autores principales: | Nagaya, Naoya, Nagata, Masayoshi, Lu, Yan, Kanayama, Mayuko, Hou, Qi, Hotta, Zen-u, China, Toshiyuki, Kitamura, Kosuke, Matsushita, Kazuhito, Isotani, Shuji, Muto, Satoru, Sakamoto, Yoshiro, Horie, Shigeo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984691/ https://www.ncbi.nlm.nih.gov/pubmed/31986176 http://dx.doi.org/10.1371/journal.pone.0226219 |
Ejemplares similares
-
Significant association between urethral length measured by magnetic resonance imaging and urinary continence recovery after robot-assisted radical prostatectomy
por: Kitamura, Kosuke, et al.
Publicado: (2019) -
Clinical use of expanded prostate cancer index composite-based health-related quality of life outcomes after robot-assisted radical prostatectomy for localized prostate cancer
por: Fukuda, Kazuhiro, et al.
Publicado: (2022) -
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
por: Hirano, Hisashi, et al.
Publicado: (2023) -
The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma
por: Nagaya, Naoya, et al.
Publicado: (2018) -
Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
por: Nagaya, Naoya, et al.
Publicado: (2020)